Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - enalaprilijev maleat - tableta - enalaprilijev maleat 20 mg / 1 tableta - enalapril

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - enalaprilijev maleat - tableta - enalaprilijev maleat 5 mg / 1 tableta - enalapril

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - enalaprilijev maleat - tableta - enalaprilijev maleat 5 mg / 1 tableta - enalapril

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - enalaprilijev maleat - tableta - enalaprilijev maleat 10 mg / 1 tableta - enalapril

Σλοβενία - Σλοβενικά - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

lek d.d. - enalapril - tableta - enalapril 7,64 mg / 1 tableta - enalapril

Ευρωπαϊκή Ένωση - Σλοβενικά - EMA (European Medicines Agency)

intervet international b.v. - inaktivirano leptospira sevov: l. interrogans serogroup serovar canicola portland-vere (sev ca-12-000); l. interrogans serogroup serovar icterohaemorrhagiae copenhageni (sev ic-02-001); l. interrogans serogroup australis serovar bratislava (seva kot-05-073); l. kirschneri serogroup grippotyphosa serovar dadas (sev gr-01-005) - immunologicals za canidae, inaktivirano bakterijska cepiva (vključno z mikroplazma, toxoid in chlamydia) - psi - za aktivno imunizacijo psov proti: l. interrogans serogroup canicola serovar canicola za zmanjšanje okužbe in izločanje urina;l. interrogans serogroup serovar icterohaemorrhagiae copenhageni za zmanjšanje okužbe in izločanje urina;l. interrogans serogroup australis serovar bratislava za zmanjšanje okužbe;l. kirschneri serogroup grippotyphosa serovar bananal / lianguang za zmanjšanje okužbe in izločanja urina.

Ευρωπαϊκή Ένωση - Σλοβενικά - EMA (European Medicines Agency)

intervet international bv - leptospira interrogans serogroup serovar canicola portland-vere (sev ca-12-000), l. interrogans serogroup serovar icterohaemorrhagiae copenhageni (sev ic-02-001), l. interrogans serogroup australis serovar bratislava (seva kot-05-073), l. kirschneri serogroup grippotyphosa serovar dadas (sev gr-01-005) - imunologija - psi - za aktivno imunizacijo psov proti:leptospira interrogans serogroup canicola serovar canicola za zmanjšanje okužbe in izločanje urina;l. interrogans serogroup serovar icterohaemorrhagiae copenhageni za zmanjšanje okužbe in izločanje urina;l. interrogans serogroup australis serovar bratislava za zmanjšanje okužbe;l. kirschneri serogroup grippotyphosa serovar bananal / lianguang za zmanjšanje okužbe in izločanja urina.

Ευρωπαϊκή Ένωση - Σλοβενικά - EMA (European Medicines Agency)

takeda pharmaceuticals international ag ireland branch - velagluceraza alfa - gaucher bolezen - drugi zdravljene bolezni prebavil in presnove izdelki, - vpriv je indiciran za dolgoročno encimsko nadomestno zdravljenje (ert) pri bolnikih z gaucherjevo boleznijo tipa 1.

Ευρωπαϊκή Ένωση - Σλοβενικά - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - ipilimumab - melanoma; carcinoma, renal cell; carcinoma, non-small-cell lung; mesothelioma, malignant; colorectal neoplasms - antineoplastična sredstva - melanomayervoy as monotherapy or combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (see section 4.  yervoy in combination with nivolumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. relative to nivolumab monotherapy, an increase in progression-free survival (pfs) and overall survival (os) for the combination of nivolumab with ipilimumab is established only in patients with low tumour pd-l1 expression (see sections 4. 4 in 5. renal cell carcinoma (rcc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with intermediate/poor-risk advanced renal cell carcinoma (see section 5. non-small cell lung cancer (nsclc)yervoy in combination with nivolumab and 2 cycles of platinum-based chemotherapy is indicated for the first-line treatment of metastatic non-small cell lung cancer in adults whose tumours have no sensitising egfr mutation or alk translocation. malignant pleural mesothelioma (mpm)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable malignant pleural mesothelioma. mismatch repair deficient (dmmr) or microsatellite instability-high (msi-h) colorectal cancer (crc)yervoy in combination with nivolumab is indicated for the treatment of adult patients with mismatch repair deficient or microsatellite instability-high metastatic colorectal cancer after prior fluoropyrimidine based combination chemotherapy (see section 5. oesophageal squamous cell carcinoma (oscc)yervoy in combination with nivolumab is indicated for the first-line treatment of adult patients with unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma with tumour cell pd-l1 expression ≥ 1%.

Ευρωπαϊκή Ένωση - Σλοβενικά - EMA (European Medicines Agency)

eli lilly nederland b.v. - olanzapin pamoat - shizofrenija - psiholeptiki - vzdrževalno zdravljenje odraslih bolnikov s shizofrenijo, ki so se med akutnim zdravljenjem z oralno olanzapinom dovolj stabilizirali.